Custodes Futurifor the advancement of humanity

Katalin Karikó born 1955

Contribution. With Drew Weissman, she showed in 2005 what happens when some building blocks of synthetic mRNA (nucleosides) are replaced with modified versions found in nature, such as pseudouridine. The change greatly reduces the mRNA's activation of the innate immune system. That immune response had caused inflammation (Immunity, 2005). This made mRNA vaccines, including COVID-19 vaccines, possible. She shared the 2023 Nobel Prize in Physiology or Medicine with Weissman.

At a glance

ItemDetail
Datesborn 1955
FieldMedicine and public health
Case typePioneer
Discrimination or exclusionYes (suspected, not documented)

Factor coverage

Favorable entries (helped or barrier absent) and adverse entries (barrier or not overcome) by factor. Factor tags are this site's classification.

Barriers faced

FactorsStatement
Economic EducationalA modest start. She grew up in Kisújszállás, a town of about 10,000. She was the daughter of a butcher and a bookkeeper. Her home had no running water and no television. One of her teachers told her he would make sure she did not go to university (NobelPrize.org).
Societal EconomicFunding loss and leaving Hungary. In 1985 her research group at the Biological Research Centre in Szeged ran out of funding. Her position was eliminated. In her own account, communist Hungary let emigrants take only $50 each, and the family had $100. They sold their car. They exchanged the money on the black market for about 800 British pounds (Nobel interview, 2023). They sewed it into their two-year-old daughter's teddy bear. NobelPrize.org's profile gives the sum as a little more than $1,000 (NobelPrize.org).
Social SocietalA hostile supervisor. According to her memoir, as summarized in a 2024 review in Emerging Infectious Diseases, her supervisor at Temple University screamed and threw objects at her. The same account says that when she tried to leave, the supervisor threatened to have her deported.
Societal Economic CulturalRejection and demotion at Penn. She worked at the University of Pennsylvania from 1989. There her grant applications were rejected one after another. This was because few scientists thought unstable mRNA could become a medicine (University of Szeged). In 1995 she was demoted off the path to a full professorship. That same year she had a cancer scare, and a visa problem held her husband in Hungary. She described being demoted four times.
Social CulturalLittle interest in the 2005 finding. She and Weissman expected their 2005 finding to draw wide interest. But, in her words, "Nobody cared." A 2023 perspective in Frontiers in Immunology, citing the New York Times, reports that Nature and Science rejected the manuscript before Immunity published it.

What helped

FactorsStatement
Educational Societal EconomicA path for working-class students. From age 16 she spent two summers in university preparatory courses for children of working-class parents. In 1973 she ranked third of 15 students admitted to study biology at the University of Szeged. She earned a PhD in biochemistry there in 1982.
Educational SocialEarly influences. Two things fed her interest in biology: a biology teacher, Albert Tóth, and her father's work as a butcher. At 16 she read a Hungarian translation of a book by the endocrinologist Hans Selye. He advised focusing on what one can change, and she later cited that advice.
Educational TechnologicalTraining in an RNA laboratory. Jenő Tomasz's group at the Biological Research Centre in Szeged worked on nucleotide chemistry. She first used a modified nucleoside there.
SocialA chance meeting. In the late 1990s she met the immunologist Drew Weissman at a photocopier. On her advice, he switched his vaccine work from DNA to mRNA.
EconomicA collaborator's funding. Weissman's grants kept her work going. From 2006 the two won National Institutes of Health funding together.
PsychologicalPersistence. After her demotion she kept "working like nothing happened." She and Weissman spent years finding the cause of the inflammation that synthetic mRNA caused in mice and in human immune cells.
Economic SocietalA private-sector path. In 2013 she joined BioNTech in Mainz, Germany, as vice president. She became senior vice president in 2019. Her husband backed the move. She commuted between Philadelphia and Germany for about nine years.

Not overcome

FactorsStatement
SocietalShe never held a tenured post. She stayed in non-tenured positions at Penn until 2013. That year the university declined to reinstate her former position and told her she was "not of faculty quality." She was forced to retire after 24 years. RNARx, the company she and Weissman founded, could not get the patent rights to their discovery. Penn owned those rights and licensed them.

Notes

FactorsStatement
Societal SocialPossible bias. Some commentators, including UC Berkeley biologist Michael Eisen, have suggested that she was penalized for being a woman and an immigrant from Eastern Europe (Times Higher Education). This is a suggestion, not a documented finding. Penn did not respond to questions. Penn says the Pfizer/BioNTech and Moderna vaccines use its licensed technology and that Penn, Karikó, and Weissman have received financial benefits from it. Her memoir, Breaking Through: My Life in Science, was published by Crown in 2023.

Discrimination and exclusion

ElementIn this case
Form of exclusionRepeated demotions. Bias against her as a female immigrant is suspected but not documented.
Modern evidence it parallelsExperimental evidence on gender bias in academic hiring is mixed (rated D and B). So the document does not treat bias as established in her case.
What got them past itHer collaborator Drew Weissman and a private-sector path.

Pattern summary

ElementIn this case
Door-openerWeissman
Knowledge sourceSzeged doctorate and RNA laboratory
Institutional supportWeissman's grants, NIH from 2006, BioNTech
Built on recent workRNA research base
Setback overcomeEmigration, demotion
Barrier not overcomeNever granted tenure

Sources

  1. CNBC: Karikó demoted four times
  2. Times Higher Education: Karikó's Nobel
  3. MedicalBrief: Researcher demoted by university wins Nobel
  4. Karikó, K., Buckstein, M., Ni, H., and Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165-175
  5. NobelPrize.org. Women who changed science: Katalin Karikó
  6. NobelPrize.org. (2023). Katalin Karikó, Interview (telephone interview, October 2023, and December 2023 interview)
  7. NobelPrize.org. (2023). Katalin Karikó, Facts
  8. University of Szeged Klebelsberg Library. Katalin Karikó exhibition: Bio
  9. University of Szeged Klebelsberg Library. Katalin Karikó exhibition: University years in Szeged
  10. University of Szeged Klebelsberg Library. Katalin Karikó exhibition: Biological Research Center, Szeged
  11. University of Szeged Klebelsberg Library. Katalin Karikó exhibition: Research in the U.S.
  12. Keller, S. C. (2024). Book review: Breaking Through: My Life in Science. Emerging Infectious Diseases, 30(4), 839
  13. Bansal, A. (2023, November 8). From rejection to the Nobel Prize: Karikó and Weissman's pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology. Frontiers in Immunology, 14
  14. National Women's History Museum. (2021). Kati Karikó
  15. Penn Today. (2023, October 2). Katalin Karikó and Drew Weissman, Penn's historic mRNA vaccine research team, win 2023 Nobel Prize in Medicine

Also relevant: Bell, A., Chetty, R., Jaravel, X., Petkova, N., & Van Reenen, J. (2019). Who becomes an inventor in America? Quarterly Journal of Economics, 134(2), 647-713. All references